Urinary System Tumor

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Urinary System Tumor is an early-stage landscape with 0 programs across 1 company. The most active players are Sichuan Baili Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Sichuan Baili Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Not yet recruiting1 · 33%

Unknown status1 · 33%

Recruiting1 · 33%

Clinical Trials

Trial Activity

A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors

Not yet recruiting·TTongji Hospital·Phase 2·NCT06427057·40 enrolled

A Clinical Study to Evaluate Safety, Tolerance, Pharmacokinetics and Efficacy of Sc610 Injection for Treating Advanced Urinary System Tumors

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05633589·45 enrolled

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT05785039·76 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)